Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NCNA 
NuCana PLC (NCNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: NCNA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $104
1 Year Target Price $104
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.38% | Avg. Invested days 15 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.67M USD | Price to earnings Ratio - | 1Y Target Price 104 |
Price to earnings Ratio - | 1Y Target Price 104 | ||
Volume (30-day avg) 1 | Beta 1.51 | 52 Weeks Range 2.78 - 368.00 | Updated Date 10/23/2025 |
52 Weeks Range 2.78 - 368.00 | Updated Date 10/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1742.53 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -71.53% | Return on Equity (TTM) -567.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -2338338 | Price to Sales(TTM) - |
Enterprise Value -2338338 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.3 | Shares Outstanding 1908078 | Shares Floating 9539268049 |
Shares Outstanding 1908078 | Shares Floating 9539268049 | ||
Percent Insiders - | Percent Institutions 0.45 |
Upturn AI SWOT
NuCana PLC
Company Overview
History and Background
NuCana PLC, founded in 1997, is a biopharmaceutical company focused on developing medicines to treat cancer by overcoming key resistance mechanisms. It has transitioned from focusing solely on ProTide technology to a broader oncology focus.
Core Business Areas
- Oncology Drug Development: NuCana focuses on developing novel cancer therapies, primarily using its ProTide technology.
Leadership and Structure
Hugh S. Griffith serves as the Chief Executive Officer. The company has a board of directors overseeing strategic direction and governance.
Top Products and Market Share
Key Offerings
- Acelarin: Acelarin is a ProTide transformation of gemcitabine, designed to overcome key cancer resistance mechanisms. While it has not reached market release, clinical trials have been completed and previous clinical trial results were promising. Competitors include generic gemcitabine and other chemotherapeutic agents.
- NUC-3373: NUC-3373 is a ProTide transformation of 5-fluorouracil (5-FU), another common chemotherapeutic agent. It is currently in development. Competitors are generic 5-FU and targeted therapies. Clinical trials have been completed and previous clinical trial results were promising.
Market Dynamics
Industry Overview
The oncology market is large and growing, with significant unmet needs for more effective and less toxic cancer treatments.
Positioning
NuCana aims to differentiate itself by developing ProTide versions of established chemotherapies, hoping to improve their efficacy and reduce resistance.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. NuCana targets specific segments within this market where its ProTide technology may offer an advantage. Specific TAM for their drugs is not readily available and requires in-depth market analysis.
Upturn SWOT Analysis
Strengths
- ProTide technology platform
- Potential for improved efficacy and reduced resistance of chemotherapies
- Experienced management team
Weaknesses
- Reliance on a single technology platform
- Dependence on clinical trial success
- Limited financial resources
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Positive clinical trial data driving market adoption
Threats
- Competition from established chemotherapies and novel therapies
- Regulatory hurdles
- Clinical trial failures
- Financial constraints
Competitors and Market Share
Key Competitors
- GILD
- MRK
- PFE
Competitive Landscape
NuCana faced intense competition from large pharmaceutical companies with established oncology portfolios. Its success depended on demonstrating a clear advantage of its ProTide technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was dependent on clinical trial progress and partnerships.
Future Projections: Future growth hinges on successful clinical development and commercialization strategies. Analyst estimates are currently unavailable.
Recent Initiatives: Recent initiatives focused on advancing its ProTide candidates through clinical trials. Delisting from the stock market has changed its focus.
Summary
NuCana PLC was a biopharmaceutical company with a promising technology platform but faced significant challenges in a competitive market. Its future depends on clinical trial outcomes and securing funding. Its delisting from the stock market shows it is struggling to sustain itself. It will need to improve its competitive positioning to thrive.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website, SEC filings (historical), Analyst reports (historical)
Disclaimers:
This analysis is based on publicly available information and historical data. The company is no longer listed, so updated financial information is not available. Market conditions and company performance can change rapidly. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NuCana PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2017-09-28 | Founder, CEO & Executive Director Mr. Hugh Stephen Griffith | ||
Sector Healthcare | Industry Biotechnology | Full time employees 20 | Website https://www.nucana.com |
Full time employees 20 | Website https://www.nucana.com | ||
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1 modular clinical trial for patients with advanced solid tumors and lung cancer. The company is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.